Immunome’s $334k sale lands as biotech stays choppy

Biotech has not been a one-way tape. XBI was down about 1.4% over the most recent reported week, IBB slipped 0.5%, and both funds still sit well ahead year to date, which tells you the group has room to run and room to give it back. That is the setting for Immunome, a development-stage oncology and antibody-drug conjugate name where the stock still trades more like a catalyst vehicle than a slow compounder.

The company matters because its business model is built around clinical progress, not recurring revenue. You are paying for pipeline optionality, for data, for deal flow, and for the market’s willingness to keep funding that story while rates and risk appetite move around. In that kind of name, the stock can ignore fundamentals for stretches, then reprice hard when the market decides the next readout or financing matters more than the last one.

What Immunome sells, and why the stock moves when it does

Immunome Inc. sits in the part of biotech where the balance sheet, the pipeline, and the calendar all matter at once. The company is focused on antibody-drug conjugates and oncology therapeutics, which means the market is not valuing a current earnings stream so much as the probability that one or more programs can survive the usual gauntlet of preclinical work, clinical data, and partnering interest. That is why the stock can trade with the sector one week and then decouple the next.

The peer set in the research points in the same direction. Larger oncology names such as Genmab have been using acquisitions and pipeline expansion to deepen their positions in bispecifics and ADCs, while smaller names like TRACON Pharmaceuticals or Galectin Therapeutics sit in overlapping therapeutic territory with very different market caps and clinical-stage profiles. Immunome is not being compared with a utility. It is being compared with other shots on goal, and the market tends to price those names on the next visible event rather than on a tidy long-term model.

That is also why rates still matter here. Higher rates have historically pressed on growth-oriented biotech, especially names that may need capital before they need profits. When the macro backdrop gets less forgiving, the market gets less patient with long-duration cash flows. When the sector catches a bid, the same names can rerate quickly because the market is buying time as much as science.

The stock’s own recent action reflects that tension. Immunome closed at $23.95 on September 15, down 2.4% on the day, with a market capitalization of approximately $2.8 billion. Analysts, according to the research cited here, still lean Moderate to Strong Buy with average price targets in the mid-$30s, so the market is not treating this as a broken story. It is treating it as a volatile one.

Jack Higgins sold again, and the filing sits inside a larger pattern

The latest filing came from Jack Higgins, Immunome’s Chief Scientific Officer. He sold 13,200 shares on September 11 at an average price of $25.32 per share, for a euro-normalised filing value of EUR 334,224. He retained 65,050 shares directly afterward, and the transaction followed option exercises under a pre-established Rule 10b5-1 trading plan adopted in December 2025.

That matters because this was not a one-off. It lands inside a broader run of insider selling at Immunome through mid-2026, with director Isaac Barchas, Chief Business Officer Kinney Horn, Chief Medical Officer Robert Lechleider, and CFO Max Rosett all executing multiple sales between June and August. The research points to hundreds of thousands of shares and several million dollars in proceeds across that stretch. Higgins’ sale is smaller than some of the earlier disposals, but it does not arrive in isolation.

The market usually gives more weight to a single large open-market sale from a lone insider than to a planned sale under 10b5-1. Fair enough. But clusters are different. When several senior people and a director group are all monetizing around the same window, you are no longer reading one person’s tax bill or portfolio housekeeping. You are reading a pattern of distribution around the same name.

Our scoring leans on that pattern, plus the fact that the filing came from an operating director-level insider and was sized at about 0.01% of the company’s market value. The euro-normalised value was near EUR 287,667 in the internal signal record, which is not a giant number in a $2.8 billion company, but it is not nothing either. In a biotech where the stock can move on sentiment and calendar risk, repeated selling by senior insiders is the sort of thing you notice because it lines up with how these names often trade around event windows.

The cluster is the point, even if the plan blunts the edge

The cleanest mistake a reader can make here is to treat the 10b5-1 label as a full explanation. It is not. A pre-arranged plan tells you the trade was scheduled, not that the timing is meaningless. It also does not erase the fact that the same company has seen a string of insider disposals across several roles in a relatively tight window.

InsiderTrades data shows a cluster at Immunome, with three distinct insiders and 12 recent declarations in the record we are looking at. The recent list includes multiple entries for Higgins on September 15 and September 11, plus Barchas on August 12. That is enough to say the selling has been persistent, not episodic. It is also enough to say the market has had repeated chances to absorb insider supply.

The important part is what this does and does not tell you about the stock. It tells you senior people have been willing to sell into a period when the sector has still been constructive on a year-to-date basis but choppy in the short run. It does not tell you the pipeline is weak, or that a data readout will disappoint, or that the stock cannot keep working if the next catalyst lands well. Biotech has a habit of humiliating anyone who confuses insider behavior with a full fundamental verdict.

Still, clusters matter because they often show up when the market is already giving insiders a decent exit. Higgins sold at $25.32 per share. The stock later closed at $23.95 on September 15. That gap is not a thesis by itself, but it does show the market has not been rewarding the name with a straight line higher. In a sector where timing is half the game, that is enough to keep the filing on the desk.

Our cohort read, and the part you should not overread

The historical cohort data in the dossier is for director-level buys at mid-cap names, not for this exact sale, and not for Immunome specifically. That bucket has a sample size of 5,339, a 54.1% 90-day win rate, a 5.85% average 90-day return, and a 94.18% average 365-day return. Those are useful context, because they tell you the broader role-and-size bucket has not been useless. They are not a promise that a biotech with a selling cluster will behave the same way.

You should also keep the bucket mismatch in view. The cohort stat is for buys, while the filing here is a sale. That is exactly why the number belongs in the article as context rather than as a verdict. It gives you a sense of how our historical framework has behaved in a similar size band and role band, but it does not convert a disposal into a buy signal or a buy signal into a disposal signal.

The strategy headline in the dossier is also a screen, not a prophecy. The live tokens are 0.81, 26.4, and 51.5, and they apply to a restricted EU venue universe with a short, single-regime window. They are useful if you want to know how the framework has behaved in that environment, but they are not a reason to ignore the company-specific facts in front of you.

Why the market may still care about Immunome anyway

The reason Immunome keeps showing up in the conversation is that the stock still has a real catalyst structure. Development-stage oncology names do not need a lot of narrative help when the market is willing to pay for pipeline progress. They need data, financing clarity, and enough sector support that the next event can be financed and traded. Immunome has enough analyst support, enough market value, and enough sector relevance to stay on screens.

That is why the insider selling does not automatically break the story. The company is still in a part of biotech where a favorable readout, a partnership, or a broader rotation into healthcare can matter more than a handful of sales. XBI and IBB both remain positive year to date even after the recent wobble, and large-cap healthcare has shown relative resilience in the latest sessions. If the sector keeps rotating, Immunome can catch a bid with it.

But the stock is also vulnerable to the same forces that have made biotech choppy. Clinical readouts can disappoint. Regulatory decisions can slip. Financing conditions can tighten. Higher rates can keep pressure on long-duration names. The market does not need a disaster to punish a development-stage biotech. It only needs a reason to prefer something else for a while.

That is the tension here. The insider cluster says senior people have been taking money off the table through the summer and into September. The sector backdrop says biotech still has support, but not enough to make every name easy. The company’s business model says the stock will keep moving on catalysts, not on a smooth earnings cadence. Put those together and you get a name that deserves attention, but not blind faith.

What to watch after the September 11 sale

The next useful question is not whether one sale proves anything. It is whether Immunome keeps printing the same pattern. If more senior insiders sell after Higgins, the cluster becomes harder to treat as background noise. If the company instead gets a catalyst that changes the market’s view of the pipeline, the selling will look more like well-timed monetization around a volatile biotech tape.

You should also watch whether the stock can hold up relative to the sector. XBI and IBB have both been volatile, but they remain constructive on a year-to-date basis. If Immunome starts lagging even when biotech firms up, the insider pattern will matter more. If it outperforms into a sector bid, the market is telling you it cares more about the next event than about the summer’s selling.

The other thing to watch is whether the company’s market value keeps giving insiders room to sell without forcing a broader re-rating. At roughly $2.8 billion, Immunome is large enough that the market can absorb some supply, but not so large that repeated insider disposals are meaningless. That is the middle ground where these filings tend to matter most. They do not decide the stock. They do tell you who has been willing to cash out while the market still pays up.

The filing on September 11 is therefore best read as part of a sequence, not as a standalone alarm. Immunome remains a catalyst-driven biotech with a live pipeline story, a choppy sector backdrop, and a summer of insider selling that has not yet stopped. The next public data point, whether clinical or corporate, will matter more than the filing itself, and the market will tell you quickly whether it prefers the science or the supply.

This is not investment advice.